Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD133+ endothelial progenitor cells + percutaneous transluminal angioplasty
- Development stage
- Unknown
- Lead developer
- Shanghai Tenth People's Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
This is an autologous cell therapy consisting of CD133+ endothelial progenitor cells (EPCs) administered in conjunction with percutaneous transluminal angioplasty (PTA). Developed by Shanghai 10th People's Hospital, the treatment is designed for patients with diabetic foot and infrapopliteal peripheral arterial disease. The process involves isolating CD133+ cells from the patient's peripheral blood mononuclear cells using magnetic-activated cell sorting. Following successful revascularization via PTA, these cells are infused intra-arterially into the popliteal artery of the affected limb. The EPCs are intended to integrate into damaged vascular endothelium and promote angiogenesis through paracrine signaling and direct integration, thereby improving microcirculation and wound healing in the diabetic foot.
- Other names
- EPCs plus PTAautologous CD133+ cells + PTAautologous endothelial progenitor cells + percutaneous transluminal angioplasty
Beyond the preview
Go deeper on autologous CD133+ endothelial progenitor cells + percutaneous transluminal angioplasty.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD133+ endothelial progenitor cells + percutaneous transluminal angioplasty.